Recursion outlines $375M 2026 cash OpEx guidance while advancing first Genentech neuroscience target

We are no longer just discussing the potential of our platform." (CEO, President & Director Najat Khan) "We now have 5 clinical stage programs, including REC-4881 in FAP, where we have generated some ...
pharmaphorum

Change at the top of Recursion as co-founder leaves CEO role

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...